American Society of Clinical Oncology (ASCO)
Join Xcenda's consulting team at ASCO on June 4-8, 2010. Learn more about our work that has been accepted for both publication and poster presentations.
Abstract Control Number: 53859
Permanent Abstract ID: 6601
General Poster Session: Leukemia, Myelodysplasia, and Transplantation
Sunday, June 5, 8:00 AM – 12:00 PM
S Hall A2
Poster: 20C
- Hematologic outcomes of MDS treatment with hypomethylating agents in community practice.
Authors:
R. Bordoni, B. A. Feinberg, J. W. Gilmore, S. Haislip, E. Kim, J. Rege, J. Jackson, E. Farrelly, D. Buchner; Georgia Cancer Specialists PC, Marietta, GA; Georgia Cancer Specialists PC, Atlanta, GA; Eisai, Inc., Woodcliff Lake, NJ; Xcenda, Palm Harbor, FL
Abstract Control Number: 54273
Permanent Abstract ID: 8146
General Poster Session: Lymphoma and Plasma Cell Disorders
Saturday, June 5, 8:00 AM – 12:00 PM
S Hall A2
Poster: 38H
- Does the magnitude of response to initial induction therapy impact plans for immediate autologous stem cell transplant (ASCT) consolidation in the transplant-eligible patient with a new diagnosis of multiple myeloma (MM)?
Authors:
J. Willey, K. E. Lemke, M. E. Williams, M. R. Green, S. Lonial
Xcenda, Palm Harbor, FL; University of Virginia Medical Center, Charlottesville, VA; Winship Cancer Institute at Emory University, Atlanta, GA
Abstract Control Number: 51618
Permanent Abstract ID: 7568
General Poster Session: Lung Cancer
Sunday, June 6, 8:00 AM – 12:00 PM
S Hall A2
Poster: 37E
- Plans of American medical oncologists (AMO) to order molecular testing before starting first-line therapy for patients with stage IV non-small cell lung cancer (NSCLC)
Authors:
M. R. Green, A. J. Wozniak, J. Willey, K. E. Lemke, H. J. West
Xcenda, Palm Harbor, FL; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Swedish Cancer Institute, Seattle, WA
Abstract Control Number: 51612
Permanent Abstract & Poster ID: 4565
Poster Discussion Session
Monday, June 7 8:00 AM – 12:00 PM
E Hall D2 / E450a
Presenter: Eric Kruep, PharmaD, MS
- Using prostate-specific antigen threshold to identify increased 4-year risk of prostate cancer
Authors:
E. David Crawford, MD, Judd W. Moul, MD, Curtis Pettaway, MD, Scott Sutton, PharmD, BCPS, Sara Poston, PharmD, and Michael Eaddy, PharmD, PhD
University of Colorado Health Sciences Center, Denver, CO; Division of Urologic Surgery, Duke University Medical Center, Durham, NC; MD Anderson Cancer Center, University of Texas, Houston, TX; South Carolina College of Pharmacy, University of South Carolina, WJB Dorn Veterans Affairs Medical Center, Columbia, South Carolina; GlaxoSmithKline, Collegeville, PA; and Xcenda, LLC, Palm Harbor, FL
Abstract Control Number: 54232
Permanent Abstract ID: e14617
Accepted for publication
- Plans among American medical oncologists (AMO) for inclusion of trans-arterial chemo-embolization (TACE) as part of first-line therapy in patients with liver-only hepatocellular carcinoma (HCC) not amenable to surgical therapy
Authors:
S. Britton, M. Morse, M. R. Green, J. Willey, K. E. Lemke, J. Marshall
Xcenda, Palm Harbor, FL; Duke University Medical Center, Durham, NC; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC